Patents by Inventor Christian Griesinger
Christian Griesinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11744839Abstract: Method of increasing platelet counts in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound that inhibits Biliverdin reductase B (BLVRB) activity by blocking a binding site of BLVRB or a pharmaceutically acceptable salt thereof, wherein the compound does not contain xanthene or acridine moiety is provided.Type: GrantFiled: April 7, 2021Date of Patent: September 5, 2023Assignees: KOREA BASIC SCIENCE INSTITUTE, University of Louisville Research Foundation, Inc., Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Kyoung-Seok Ryu, Myeongkyu Kim, Christian Griesinger, Donghan Lee
-
Publication number: 20230067910Abstract: The present invention relates to compounds represented by general formula (Ia), (Ib), (IIa) or (IIb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.Type: ApplicationFiled: November 19, 2020Publication date: March 2, 2023Applicants: MODAG GMBH, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Armin GIESE, Felix SCHMIDT, Daniel WECKBECKER, Andrei LEONOV, Sergey RYAZANOV, Christian GRIESINGER, Bernd PICHLER, Kristina HERFERT, Andreas MAURER, Laura KÜBLER, Sabrina BUSS
-
Publication number: 20220339170Abstract: Method of increasing platelet counts in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound that inhibits Biliverdin reductase B (BLVRB) activity by blocking a binding site of BLVRB or a pharmaceutically acceptable salt thereof, wherein the compound does not contain xanthene or acridine moiety is provided.Type: ApplicationFiled: April 7, 2021Publication date: October 27, 2022Inventors: Kyoung-Seok RYU, Myeongkyu KIM, Christian GRIESINGER, Donghan LEE
-
Patent number: 11180518Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.Type: GrantFiled: May 11, 2018Date of Patent: November 23, 2021Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
-
Publication number: 20200165279Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.Type: ApplicationFiled: May 11, 2018Publication date: May 28, 2020Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GEORG-AUGUST-UNIVERSITÄT GÖTTINGENInventors: Dorothea BECKER, Thomas M. JOVIN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Armin GIESE, Tiago F. OUTEIRO, Diana F. LAZARO, Michael P. SCHÖN, Margarete SCHÖN
-
Patent number: 10435373Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.Type: GrantFiled: August 3, 2018Date of Patent: October 8, 2019Assignees: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
-
Patent number: 10308671Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.Type: GrantFiled: December 14, 2016Date of Patent: June 4, 2019Assignee: Max-Planck-Gesellschaft zur ForderungInventors: Armin Giese, Felix Schmidt, Christian Griesinger, Andrei Leonov, Sergey Ryazanov
-
Publication number: 20180370997Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.Type: ApplicationFiled: December 14, 2016Publication date: December 27, 2018Applicants: Max-Planck-Gesellschaft zur FörderungInventors: Armin GIESE, Felix SCHMIDT, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV
-
Publication number: 20180346426Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.Type: ApplicationFiled: August 3, 2018Publication date: December 6, 2018Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V.Inventors: Armin GIESE, Uwe BERTSCH, Hans KRETZSCHMAR, Matthias HABECK, Thomas HIRSCHBERGER, Paul TAVAN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Petra FRICK née WEBER, Markus GEISSEN, Martin H. GROSCHUP, Jens WAGNER
-
Patent number: 10071966Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.Type: GrantFiled: December 22, 2015Date of Patent: September 11, 2018Assignees: LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick, Markus Geissen, Martin H. Groschup, Jens Wagner
-
Publication number: 20160185730Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.Type: ApplicationFiled: December 22, 2015Publication date: June 30, 2016Applicants: Ludwig-Maximilians-Universität München, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
-
Patent number: 9253964Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: GrantFiled: July 8, 2014Date of Patent: February 9, 2016Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
-
Patent number: 9247721Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: GrantFiled: July 8, 2014Date of Patent: February 2, 2016Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
-
Publication number: 20150143556Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: ApplicationFiled: July 8, 2014Publication date: May 21, 2015Inventors: Markus ZWECKSTETTER, Pinar KARPINAR, Christian GRIESINGER
-
Publication number: 20150125951Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: ApplicationFiled: July 8, 2014Publication date: May 7, 2015Inventors: Markus ZWECKSTETTER, Pinar KARPINAR, Christian GRIESINGER
-
Patent number: 8809505Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: GrantFiled: August 7, 2009Date of Patent: August 19, 2014Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
-
Publication number: 20110293520Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R1)(R2)—, —C(R3)?, —N(R4)—, —N?, —N+(R5)?, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).Type: ApplicationFiled: June 9, 2009Publication date: December 1, 2011Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Mathias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
-
Publication number: 20110296539Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: ApplicationFiled: August 7, 2009Publication date: December 1, 2011Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
-
Patent number: 5939527Abstract: The present invention provides anti-tumor peptides of Formula I,A--B--NR.sup.3 --CHD--CH(OCH.sub.3)--CH.sub.2 CO--E--K (I),and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N,N-dimethyl-2-ethylphenylglycyl, or an amino acid residue of the formula R.sup.1 R.sup.2 N--CHX--CO, wherein R.sup.1 is a-methyl group or an ethyl group, R.sup.2 is a hydrogen atom, a methyl group or an ethyl group, and X is an alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. R.sup.3 is a hydrogen atom or a methyl group. D is a normal or branched C.sub.2 -C.sub.5 -alkyl group. E is an amino acid residue selected from the group consisting of prolyl, homoprolyl, 5-methylprolyl, and phenylalanyl, or E is a residue derived from an amino acid comprising a pyrrolidine group. K is an alkoxy group or an amino group.Type: GrantFiled: July 30, 1996Date of Patent: August 17, 1999Assignee: BASF AktiengesellschaftInventors: Teresa Barlozzari, Andreas Haupt, Bernd Janssen, Christian Griesinger, Daniel Belik, Michael Boretzky
-
Patent number: 5741892Abstract: The present invention provides anti-tumor peptides of Formula I,A-B-N (CH.sub.3)-CHD-CH(OCH.sub.3)-CH.sub.2 CO-Pro-Pro-K (I),and the acid salts thereof. A is an amino acid residue of the formula (CH.sub.3).sub.2 N--CHX--CO, wherein X is a normal or branched alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. D is a normal or branched C.sub.3 -C.sub.4 -alkyl group. K is a t-butoxy group or a substituted amino group.An additional embodiment of the present invention is a method for treating a malignancy in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound or compounds of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: July 30, 1996Date of Patent: April 21, 1998Assignee: Basf AktiengesellschaftInventors: Teresa Barlozzari, Andreas Haupt, Bernd Janssen, Christian Griesinger, Daniel Belik, Michael Boretzky, George R. Pettit